SCHEMBL7477480

SCHEMBL7477480

c1ccc(COc2ccc(Cn3ccnc3)cc2)cc1

nearest known ligand 0.75

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HMOX1 P09601 1/20 0.75
CYP11B1 P15538 7/20 0.71
CYP11B2 P19099 7/20 0.71
CYP19A1 P11511 6/20 0.71
TBXAS1 P24557 3/20 0.71
QPCT Q16769 2/20 0.71
CYP1A2 P05177 1/20 0.71
POLB P06746 1/20 0.71
CYP3A4 P08684 1/20 0.71
CYP2D6 P10635 1/20 0.71
MAPT P10636 1/20 0.71
CYP4Z1 Q86W10 1/20 0.71
QPCTL Q9NXS2 1/20 0.71
CYP17A1 P05093 1/20 0.63
LTA4H P09960 1/20 0.60
FNTA P49354 1/20 0.60
FNTB P49356 1/20 0.60
PGGT1B P53609 1/20 0.60
KMT2A Q03164 1/20 0.59
CYP2A6 P11509 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11701053 0.88 CYP11B1 (0.73) HMOX1CYP11B1CYP11B2CYP19A1TBXAS1
SCHEMBL11705239 0.87 CYP11B1 (0.74) HMOX1CYP11B1CYP11B2CYP19A1TBXAS1
SCHEMBL17407551 0.87 CYP11B1 (0.64) HMOX1CYP11B1CYP11B2CYP19A1TBXAS1
SCHEMBL11702884 0.87 CYP19A1 (0.67) HMOX1CYP11B1CYP11B2CYP19A1TBXAS1
SCHEMBL11701540 0.87 CYP19A1 (0.74) HMOX1CYP11B1CYP11B2CYP19A1TBXAS1
SCHEMBL8389054 0.87 CYP19A1 (0.68) HMOX1CYP11B1CYP11B2CYP19A1TBXAS1
SCHEMBL31307697 0.86 CYP19A1 (0.74) HMOX1CYP11B1CYP11B2CYP19A1TBXAS1
SCHEMBL8390116 0.85 TBXAS1 (0.65) HMOX1CYP11B1CYP11B2CYP19A1TBXAS1
SCHEMBL22063900 0.84 CYP11B1 (1.00) CYP11B1CYP11B2CYP19A1TBXAS1QPCT
Benzylimidazole SCHEMBL414 0.84 CYP11B1 (1.00) CYP11B1CYP11B2CYP19A1TBXAS1QPCT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20020035092-A1 Inhibit binding of alpha-v integrins to their ligands, use in treatment of immune and inflammatory disorders; 3-(4-(2-Aminoethyl)benzamide)-3-(2-(4-(2-pyridylamino)methyl) phenoxy)-4-pyrimidinyl)propanoic acid CELLTECH THERAPEUTICS LIMITED 2002-03-21 US disclosed
US-6319922-B1 ALPHA-PYRIMIDYL-SUBSTITUTED; USEFUL FOR TREATING DISEASES INCLUDING INFLAMMATORY DISEASES, AND DISEASES INVOLVING ANGIOGENESIS, BONE RESORPTION OR CELLULAR OR MATRIX OVER-EXPANSION. CELLTECH THERAPEUTICS LIMITED (GB) 2001-11-20 US disclosed
EP-1133488-A1 PROPANOIC ACID DERIVATIVES AS INTEGRIN INHIBITORS CELLTECH THERAPEUTICS LIMITED (GB) 2001-09-19 EP disclosed
WO-2000031067-A1 PROPANOIC ACID DERIVATIVES AS INTEGRIN INHIBITORS CELLTECH THERAPEUTICS LIMITED (GB) 2000-06-02 WO disclosed
US-5100890-A Antidepressants, Fungicides HOECHST AKTIENGESELLSCHAFT (DE) 1992-03-31 US disclosed
EP-0218118-B1 ARYLMETHYL AZOLES AND THEIR SALTS, METHOD FOR THEIR PREPARATION, COMPOSITIONS CONTAINING THEM AND THEIR USE HOECHST AKTIENGESELLSCHAFT (DE) 1991-09-18 EP disclosed
US-5023357-A Arylmethylazole preparation processes HOECHST AKTIENGESELLSCHAFT (DE) 1991-06-11 US disclosed
US-4876354-A FUNGICIDES, ANTIDEPRESSANTS HOECHST AKTIENGESELLSCHAFT (DE) 1989-10-24 US disclosed
EP-0218118-A1 Arylmethyl azoles and their salts, method for their preparation, compositions containing them and their use HOECHST AKTIENGESELLSCHAFT (DE) 1987-04-15 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020035092-A1 Inhibit binding of alpha-v integrins to their ligands, use in treatment of immune and inflammatory disorders; 3-(4-(2-Aminoethyl)benzamide)-3-(2-(4-(2-pyridylamino)methyl) phenoxy)-4-pyrimidinyl)propanoic acid ITGA1, ITGB1, VCAM1 HMOX1 3504/4885CYP11B1 1957/4885CYP11B2 2766/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.